Rtw Investments 13F: Adds $353M to CG Oncology (CGON) Stake

Rtw Investments Expands Position in CG Oncology

Rtw Investments grew its stake in CG Oncology, Inc. CGON by a wide margin, according to its latest Form 13F filing with the SEC for the period ending May 15, 2026. The firm added 4,972,681 shares to its portfolio, representing a 247.1% increase from the previous quarter. That brought its total holdings to 6,984,808 shares, with an estimated value of $496.3 million based on the filing date.

CG Oncology Stock Performance

Shares of CG Oncology traded around $71.05 recently, remaining well above its 52-week low of $35.64 and approaching its 52-week high of $80.97. The biotechnology company carries a market capitalization of roughly $6.94 billion. Because the firm is a clinical-stage drug developer, it does not currently have a positive price-to-earnings ratio.

Recent Insider Activity

Insider transactions around the company included activity by James Mulay. On June 15, 2026, Mulay acquired 1,964 shares at an average price of $9.64, totaling $18,925.69 in a non-planned open market transaction. On the same date, Mulay also disposed of 1,964 shares in a transaction reported at $0.00.

Analysts Set New Price Targets

Analyst coverage remains generally optimistic across major financial firms following recent updates. On August 7, 2026, RBC Capital maintained its Outperform rating while adjusting its price target to $79.0 from $81.0. On the same day, Piper Sandler maintained its Overweight rating and lifted its price target from $82.0 to $85.0. Truist Securities also maintained its Buy rating on August 7, 2026, raising its target to $85.0 from $82.0. Overall, the stock carries a consensus recommendation key of strong buy with a mean target price of $91.08 across 13 analyst opinions.

Inside the Business

Headquartered in Dallas, Texas, CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec for patients with bladder cancer. The company's lead product candidate is an investigational oncolytic immunotherapy evaluated across multiple phase 2 and phase 3 clinical trials for high-risk and intermediate-risk non-muscle-invasive bladder cancer. Founded in 2010, the company employs 142 people.

What to Watch at CG Oncology, Inc.

Investors tracking Rtw Investments will need to wait for subsequent quarterly disclosures to see whether the fund holds or adjusts its sizeable stake further. The backward-looking nature of 13F filings means these positions reflect holdings as of the reporting date and may not represent the investor's current position today. CG Oncology's next corporate earnings update is scheduled for November 9, 2026.